Roivant Sciences Ltd. (ROIV) – What Are Analysts Saying About This Stock?

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have been assigned a consensus recommendation of “Moderate Buy” from the fourteen analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, ten have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $46.55.

Several research firms have recently commented on ROIV. Stifel Nicolaus started coverage on shares of Roivant Sciences in a report on Wednesday, September 16th. They issued a “buy” rating and a $51.00 price target for the company. Guggenheim lifted their target price on shares of Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a research note on Wednesday, September 9th. TD Cowen reissued a “buy” rating on shares of Roivant Sciences in a research report on Wednesday, October 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Roivant Sciences in a report on Wednesday, August 19th. Finally, Sanford C. Bernstein upgraded shares of Roivant Sciences to a “strong-buy” rating in a research note on Wednesday, July 29th.

Insider Transactions at Roivant Sciences

In other news, insider Mayukh Sukhatme sold 284,707 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $36.25, for a total value of $10,320,628.75. Following the sale, the insider owned 18,630,739 shares in the company, valued at $675,364,288.75. This represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Eric Venker sold 200,000 shares of the stock in a transaction dated Tuesday, October 20th. The stock was sold at an average price of $35.11, for a total value of $7,022,000.00. Following the sale, the chief executive officer directly owned 1,399,154 shares in the company, valued at $49,124,296.94. This represents a 12.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 2,022,688 shares of company stock worth $73,438,636 over the last three months. Corporate insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Roivant Sciences

Several institutional investors have recently made changes to their positions in the company. Alpine Bank Wealth Management purchased a new position in shares of Roivant Sciences in the 3rd quarter valued at about $25,000. Compass Financial Management LLC acquired a new stake in shares of Roivant Sciences during the third quarter worth about $37,000. Parallel Advisors LLC increased its holdings in shares of Roivant Sciences by 33.7% in the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock valued at $57,000 after acquiring an additional 520 shares during the period. Bessemer Group Inc. boosted its stake in shares of Roivant Sciences by 21.8% during the first quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock worth $69,000 after buying an additional 441 shares during the period. Finally, Root Financial Partners LLC raised its position in Roivant Sciences by 187.9% during the 1st quarter. Root Financial Partners LLC now owns 2,914 shares of the company’s stock worth $81,000 after buying an additional 1,902 shares during the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.

Roivant Sciences Stock Performance

ROIV opened at $36.62 on Friday. The firm’s fifty day moving average is $36.66 and its 200 day moving average is $31.72. Roivant Sciences has a fifty-two week low of $19.79 and a fifty-two week high of $42.50.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. The business had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $2.06 million. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. Equities analysts forecast that Roivant Sciences will post -2.00 earnings per share for the current fiscal year.

Roivant Sciences Company Profile

Roivant Sciences Ltd. (NASDAQ: ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines. The company organizes its activities through subsidiaries and partner companies, often referred to as “Vants,” which specialize in particular therapeutic areas and stages of drug development.

Roivant’s research and development activities have included immunology, dermatology, women’s health, rare diseases and other specialty-care fields. Its portfolio has included Vtama (tapinarof) cream, a nonsteroidal topical treatment approved in the United States for plaque psoriasis and atopic dermatitis.